Injectable weight-loss treatments such as Wegovy and Mounjaro have transformed obesity care over the past few years.
But for many people, weekly injections remain a barrier.
A needle-free alternative has been the next frontier in this field, and the UK has now taken a significant step towards it.
On 10 August 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Foundayo, making the UK the first regulator in Europe to license this once-daily weight-loss tablet.
It’s a landmark moment for anyone who has wanted the benefits of GLP-1 treatment without the injections.
What Is Foundayo?
Foundayo is the brand name for orforglipron, a medicine developed by Eli Lilly. Like Wegovy and Mounjaro, it belongs to the GLP-1 receptor agonist family, but it’s taken as a tablet rather than an injection.
It works by mimicking GLP-1, a hormone the body produces naturally.
Foundayo acts on the areas of the brain that regulate appetite, helping people feel fuller for longer and reducing cravings.
In people with type 2 diabetes, it also helps improve blood sugar control.
Foundayo is licensed for two uses:
- weight management in adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related health condition.
- improving glycaemic control in adults with type 2 diabetes whose blood sugar isn’t adequately managed.
Used alongside a reduced-calorie diet and increased physical activity, Foundayo can lead to significant weight loss.
How Effective Is Foundayo?
In a Phase III trial published in the New England Journal of Medicine in September 2025, participants taking Foundayo lost an average of 7.5% of their body weight on the 6mg dose, 8.4% on the 12mg dose, and 11.2% on the highest 36mg dose over 72 weeks, compared with 2.1% on placebo.
Those results are respectable, if a little more modest than some injectable options such as Mounjaro, which has shown larger average losses in its own trials.
Foundayo’s appeal lies less in outright potency and more in convenience.
A daily pill, which can be stored easily, is less hassle for some people compared to a weekly injection that has to be kept in the fridge.
Pill vs Injection: A Practical Comparison
For patients who are needle-phobic, uncomfortable with self-injecting, or simply want a more straightforward routine, Foundayo removes several practical hurdles.
There’s no injection technique to learn, no sharps to dispose of, and no need for fridge storage or ice packs when travelling.
The trade-off is dosing frequency.
Wegovy and Mounjaro are injected once a week, whereas Foundayo is taken once a day.
For some people, a daily tablet fits more naturally into an existing routine, such as a morning medicine round; for others, a weekly injection may be easier to remember.
Dosing and Titration
Foundayo is started at a low dose of 0.8mg once daily and gradually increased in steps, up to 2.5mg, 5.5mg, 9mg, 14.5mg, and a maintenance dose of 17.2mg.
Patients stay on each dose for a minimum of one month before stepping up, which allows the body to adjust and helps limit side effects.
No Food or Water Restrictions
One detail that sets Foundayo apart from oral Wegovy is timing.
Wegovy pills must be taken first thing in the morning on an empty stomach with a small sip of water, then followed by a 30-minute wait before eating, drinking, or taking other medicines.
That routine can be difficult to stick to.
Foundayo has no such restriction. It can be taken once a day at any time, with or without food or water, which should make it considerably easier to build into daily life.
Safety and Possible Side Effects
As with other GLP-1 medicines, the most commonly reported side effects of Foundayo are gastrointestinal:
- Nausea
- Constipation
- Diarrhoea
- Vomiting
- Indigestion
- Abdominal pain.
These tend to be most noticeable during dose increases and often ease over time.
Foundayo is a prescription-only medicine. It isn’t suitable for everyone, and eligibility depends on individual health history, so a consultation with a pharmacist or prescriber is essential before starting treatment.
Who Might Benefit Most from Foundayo?
- Adults with obesity, or overweight with a related health condition, who prefer not to self-inject
- People who are needle-phobic or find injections difficult to manage
- Frequent travellers who want to avoid carrying and storing injectable pens
- Adults with type 2 diabetes looking to improve blood sugar control alongside weight management
As with any weight-loss treatment, Foundayo is intended to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone solution.
What Happens Next?
For now, Foundayo is available only through private prescription, following a clinical consultation to confirm suitability.
It isn’t yet available on the NHS; the National Institute for Health and Care Excellence (NICE) is expected to publish its guidance on 18 November 2026, which will determine whether and how it becomes available on the NHS.
If you’d like to know whether Foundayo could be suitable for you, our team at McMinn’s Pharmacy is here to talk you through eligibility, dosing and what to expect. Speak to us today to book a personalised consultation.